Are we dealing with resistance to the chemotherapy backbone, resistance to BRAF/EGFR blockade, or both? Could serial ctDNA help identify patients who might benefit from continuing EC with an alternate chemotherapy backbone? #ESMO26
29 浏览 · 0 赞 · 0 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgImpact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.orgA provocative question for the #ESMO26 lower-GI panel: Post-BREAKWATER, if BRAF V600E mCRC progresses on FOLFOX + encorafenib/cetuximab, could we switch to FOLFIRI + EC—or vice versa? Can changing the chemo backbone preserve targeted benefit beyond progression?在 X 查看被引用的帖子
来源：Targeted Oncology · x.com